89Bio Enlivened by Nash success

Today’s mid-stage data on 89Bio’s nonalcoholic steatohepatitis project pegozafermin make the FGF21 analogue look highly competitive in what is finally shaping up to be a real market. On the twin endpoints of Nash resolution and fibrosis improvement the higher doses of pegozafermin beat almost all potential rivals on a cross-trial basis.